ORBIMED ADVISORS LLC 13D and 13G filings for Edgewise Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-11-12 5:23 pm Unchanged |
2024-11-07 | 13D | Edgewise Therapeutics, Inc. EWTX |
ORBIMED ADVISORS LLC | 14,756,096 15.600% |
0 (Unchanged) |
Filing |
| 2024-01-25 4:25 pm Purchase |
2024-01-23 | 13D | Edgewise Therapeutics, Inc. EWTX |
ORBIMED ADVISORS LLC | 14,756,096 17.300% |
454,545 (+3.18%) |
Filing |
| 2022-09-16 4:23 pm Purchase |
2022-09-16 | 13D | Edgewise Therapeutics, Inc. EWTX |
ORBIMED ADVISORS LLC | 14,301,551 23.300% |
622,496 (+4.55%) |
Filing |
| 2021-06-21 8:17 pm Purchase |
2021-06-15 | 13D | Edgewise Therapeutics, Inc. EWTX |
ORBIMED ADVISORS LLC | 3,042,764 7.300% |
3,042,764 (New Position) |
Filing |
| 2021-04-07 6:00 pm Purchase |
2021-03-30 | 13D | Edgewise Therapeutics, Inc. EWTX |
ORBIMED ADVISORS LLC | 13,679,055 27.800% |
13,679,055 (New Position) |
Filing |